Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Go back to Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study| Gilead Sciences (NASDAQ: GILD) | Delayed: 146.64 -4.35 (2.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.99 | 52 Week High | $108.63 | |||
| Open | $146.98 | 52 Week Low | $71.39 | |||
| Day High | $148.65 | P/E | 81.02 | |||
| Day Low | $145.45 | EPS | $1.81 | |||
| Volume | 6,080,505 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 148.46 -1.87 (1.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.33 | 52 Week High | $65.46 | |||
| Open | $148.41 | 52 Week Low | $47.97 | |||
| Day High | $149.60 | P/E | 100.99 | |||
| Day Low | $146.28 | EPS | $1.47 | |||
| Volume | 11,187,248 | |||||
